7:00 am - 5:00 pm
Registration & Exhibits Open
Registration is open. Check in, collect your conference materials, and take time to visit our industry partners located throughout the prefunction space.
7:00 am - 8:00 am
Breakfast Available
Enjoy a complimentary breakfast while attending the Industry Satellite Symposium. Attendees who prefer may also use this time to connect with colleagues before the day's educational program begins.
7:15 am – 7:45 am
Satellite Symposium: Supported by Camurus
This industry-supported educational symposium will feature expert faculty and the latest information from Camurus. Additional details will be available closer to the symposium. Breakfast will be provided during the session.
8:00 am – 8:10 am
Welcome & Announcements
The symposium officially begins with welcoming remarks from NANETS President Simron Singh MD, MPH, FRCPC, followed by an introduction from Symposium Chair Mintallah Haider, MD, highlighting the educational program and what attendees can expect throughout the meeting.
8:15 am – 9:15 am
Kick off the scientific program with a multidisciplinary exploration of today's most important clinical questions in neuroendocrine neoplasms. Faculty experts will present current evidence, diverse clinical perspectives, and emerging concepts followed by audience discussion.
RLT vs. Surgical debulking in Low-Grade bulky NET
Delphine Chen, MD, Director of Molecular Imaging and Therapy, Fred Hutch
Rupen A Shah, MD, FACS, Director, Peritoneal Surface Malignancy Program, Henry Ford Health
Moving beyond Morphological Classifications in NENs - Clinician Perspective
Udhayvir S. Grewal, MBBS, Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine
Moving beyond Morphological Classifications in NENs - Pathology Perspective
Laura H. Tang, MD, PhD, Attending Pathologist, Memorial Sloan Kettering Cancer Center
[Audience Discussion / Q&A]
NET MED 1: The NEN Frontier: Deciphering Today's Clinical Enigmas
Moderator: Jennifer Chan, MD, MPH, Clinical Director, Gastrointestinal Cancer Center, Director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
9:20 am – 10:20 am
Presented in collaboration with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), this joint session explores the rapidly evolving role of nuclear medicine in neuroendocrine tumor care. Expert faculty will discuss emerging evidence surrounding peptide receptor radionuclide therapy (PRRT), treatment-related toxicities, ongoing clinical trials, and considerations for specialized patient populations. The session concludes with an interactive discussion on how these advances are shaping clinical decision-making and the future of precision care.
Short-Term and Long-Term Toxicity of Alpha vs BetaPRRT: Knowns and Unknowns
Jonathan Kuten, MD, Radiologist and Nuclear Medicine Physician; Memorial Sloan Kettering Cancer Center
Nuclear Medicine Clinical Trials Updates and Implications for Clinical Decision Making in an Age of Increasing PRRT Options
Erik S. Mittra, MD, PhD, Nuclear Medicine Physician; Professor of Diagnostic Radiology, School of Medicine, Oregon Health & Science University
RLT in Specialized Populations (AYA, Geriatrics)
Jennifer R. Eads, MD, Professor of Clinical Medicine, Director, National Clinical Trials Network, University of Pennsylvania, Abramson Cancer Center
[Audience Discussion / Q&A]
Joint NANETS/SNMMI Session - Advancing Patient Care: What's Next in Nuclear Medicine Imaging and Therapy?
Moderator: Arif Sheikh, MD, Nuclear Medicine Specialist, Kettering Health
10:25 am – 11:15 am
NET Year in Review
Moderator: Kimberly Perez, MD, Senior Physician in Medical Oncology, Dana-Farber Cancer Institute
One of the symposium's featured presentations, NET Year in Review offers attendees a comprehensive look at the most significant advances shaping the field of neuroendocrine tumor care over the past year. Dr. Arvind N. Dasari will highlight influential research, emerging evidence, and key clinical developments that are impacting practice today while offering perspective on what lies ahead. The session concludes with audience discussion and expert insights.
Arvind N. Dasari, MD, MS
Professor, The University of Texas MD Anderson Cancer Center
[Audience Discussion / Q&A]
11:15 am – 11:30 am
Break
11:30 am – 12:30 pm
Explore the scientific discoveries driving the next generation of therapies for neuroendocrine neoplasms (NENs). This multidisciplinary session examines emerging therapeutic targets, advances in drug development, the evolving immune landscape of NENs, and the challenges of translating laboratory discoveries into meaningful clinical trials and patient care. Expert faculty will provide insights into the opportunities and barriers shaping the future of precision medicine for patients with NENs, followed by audience discussion.
Target Selection and Drug Engineering in NENs (Basic Science)
Nicola Fazio, MD, PhD, Director of Gastrointestinal Medical Oncology and Neuroendocrine Tumors Unit, European Institute of Oncology (IEO), Milan, Italy (ENETS President)
Immune Landscape in NENs
Jaydira Del Rivero, MD, Assistant Research Physician, Director Rare Tumor Clinic, Center for Cancer Research, National Cancer Institute
Challenges in Translating into Trials (Bench to Bedside)
Heloisa P. Soares, MD, PhD, Associate Professor, Huntsman Cancer Institute (HCI) at University of Utah
[Audience Discussion / Q&A]
NET MED 2: Exploiting Therapeutic Vulnerabilities in NENs: Progress and Challenges
Moderator: Aman Chauhan, MD, MBBS, Associate Professor of Clinical Medicine, University of California, San Francisco
12:30 pm – 1:30 pm
Satellite Symposium: Supported by Curium
Join us for an industry-supported educational symposium presented by Curium. Session title, faculty, and program details will be announced as they become available. Complimentary lunch will be served during the session.
1:35 pm – 2:35 pm
Presented in collaboration with the Society of Surgical Oncology (SSO), this multidisciplinary session explores the factors that influence risk assessment and individualized treatment planning for patients with neuroendocrine tumors. Faculty experts will examine the clinical, pathological, biological, and imaging characteristics associated with high-risk disease and discuss how these insights can guide prognosis, surveillance, and personalized therapeutic decision-making across a variety of clinical settings. The session concludes with an interactive audience discussion.
What Clinical and Pathologic Features Are Considered High-Risk for GEPNET Hepatic Recurrence and/or Overall Survival (CTC)
Callisia N. Clarke, MD, MS, FACS, FSSO, Associate Professor and Chief, Medical College of Wisconsin
Biological Bases of High Risk Disease
Arnaud Jannin, MD, Department of Endocrinology, Diabetology, and Metabolism, Centre Hospitalier Régional Universitaire de Lille (will be in Canada in Nov)
Interpreting Dual Tracer Imaging in NETs: Aligning Evidence with Practice
David Chan, MBBS, FRACP, BSc, Associate Professor, Sydney Medical School, Northern Clinical School
Risk Adapted Approach to Therapy Selection in Clinical Practice
Nitya Raj, MD, Assistant Attending Physician, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
[Audience Discussion / Q&A]
Joint NANETS/SSO Session: Refining Risk in Various Settings
Moderator: Teodora Dumitra, MD, MSc, PhD, FRCSC, Assistant Professor, Division of General Surgery, McGill University
2:35 pm – 3:05 pm
Break
5:30 pm – 6:30 pm
Beyond the Sessions: NETworking Reception
Join fellow attendees, faculty, and industry partners for an evening of networking and conversation. This informal reception provides an opportunity to strengthen existing relationships and make new connections within the neuroendocrine tumor community.
5:15 pm – 6:15 pm
NETCast Live Recordings
Be part of the conversation as NETCast, the official NANETS podcast, records live from the symposium. Attendees are invited to observe engaging discussions with faculty and special guests exploring timely topics in neuroendocrine tumor care.
Thursday, November 5, 2026
4:10 pm – 5:25 pm
Discover the latest advances in neuroendocrine tumor research during this featured oral abstract session. Selected from the highest-rated abstract submissions, these presentations highlight innovative scientific discoveries, clinical research, and emerging data that are shaping the future of NET care. Each presentation is followed by opportunities for audience engagement and discussion.
Featured Oral Abstracts I
Moderator: Daniel M. Halperin, MD, Vice Chair for Clinical Affairs, Associate Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University
3:05pm – 4:05 pm
Presented in collaboration with CUTNETS, this interactive multidisciplinary session examines emerging research through expert-led data reviews and panel discussion. Faculty representing translational science, medical oncology, and surgical oncology will explore the clinical implications of new evidence and discuss how it can be translated into real-world patient care.
Hot Topic 1: Translational Science – Study Review
Thor Halfdanarson, MD, Professor of Oncology, Mayo Clinic School of Medicine
Hot Topic 2: Systemic Therapy – Study Review
Alexandra Gangi, MD, Associate Professor, Director, Division of Surgical Oncology, Cedars-Sinai, Jim and Eleanor Randall Surgery
Hot Topic 3: Surgical Therapy – Study Review
Eleonora Pelle, MD, Post-Doctoral Researcher, Moffitt Cancer Center
[Followed by multidisciplinary panel discussion and audience participation]
Joint NANETS/CUTNETs Session: From Hot Data to Real Decisions for Interdisciplinary NET Care
Moderator: Teodora Dumitra, MD, MSc, PhD, FRCSC, Assistant Professor, Division of General Surgery, McGill University